Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 314

Sort by

Sort Order Select

Journal Articles

Hyperdiploid B-lymphoblastic leukemia/lymphoma with hypereosinophilia and very few circulating lymphoblasts

Rahul Matnani, David Weissmann

Blood (2020) 135 (12): 974.

https://doi.org/10.1182/blood.2019004647

Published: 2020

Journal Articles

Kinetics of Immune Reconstitution after CD19 CAR-T Cell Therapy in ALL Patients

Ying Wang, Jiang Cao, MD, Yan Zhiling, MD, Jianlin Qiao, PhD, Deipeng Li, MD, Zhenyu Li, MD, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 1301.

https://doi.org/10.1182/blood-2019-127808

Published: 2019

Journal Articles

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

Srividya Swaminathan, PhD, Line Dam Heftdal, MD, Daniel Liefwalker, PhD, Renumathy Dhanasekaran, MD, Anja Deutzmann, PhD, Crista Horton, BS, Adriane Mosley, BS, Mariola Liebersbach, BS, Andrew Gentles, PhD, Holden T. Maecker, PhD, Dean Felsher, MD PhD

Blood (2019) 134 (Supplement_1): 730.

https://doi.org/10.1182/blood-2019-122607

Published: 2019

Journal Articles

Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma

Xiaoyan Feng, Xin Wen, Ling Li, Xin Li, Sun Zhenchang, Lei Zhang, Lugui Qiu, MD PhD, Mingzhi Zhang, MD PhD

Blood (2019) 134 (Supplement_1): 2851.

https://doi.org/10.1182/blood-2019-130091

Published: 2019

Journal Articles

Cytokine Release Syndrome Is an Independent Risk Factor Associated with Platelet Transfusion Refractoriness after CAR-T Treatment for Relapsed/Refractory Acute Lymphoblast Leukemia

Yadan Liu, graduate student, Yongxian Hu, MD, He Huang

Blood (2019) 134 (Supplement_1): 2448.

https://doi.org/10.1182/blood-2019-129678

Published: 2019

Journal Articles

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Geoffrey L. Uy, MD, Tapan M. Kadia, MD, Wendy Stock, MD, Jonathan E Brammer, MD, Osnat Bohana-Kashtan, PhD, Abi Vainstein, Ella Sorani, PhD, Hemda Chen, PharmD, John F. DiPersio, MD PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2630.

https://doi.org/10.1182/blood-2019-127121

Published: 2019

Journal Articles

Coagulation FXIII-a Protein Expression Defines Three Novel Sub-Populations in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia Characterized By Distinct Gene Expression Signatures

Katalin Gyurina, MSc, BSc, Bettina Kárai, MD PhD, Anikó Ujfalusi, MD PhD, Zsuzsanna Hevessy, MD PhD, Gábor Barna, PhD, Pál Jáksó, MD PhD, Gyönygi Pálfi-Mészáros, Szilárd Páliska, PhD, Beáta Scholtz, PhD, János Kappelmayer, MD PhD DSc, Gábor Zahuczky, PhD, Csongor Kiss, MD PhD DSc

Blood (2019) 134 (Supplement_1): 2523.

https://doi.org/10.1182/blood-2019-124333

Published: 2019

Journal Articles

Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520

Matteo Marchesini, PhD, Andrea Gherli, Anna Montanaro, Samuel Kitara, Claudia Sorrentino, Luca Pagliaro, Anne-Marie Lund Winter, Chiara Rompietti, Donatella Stilli, Federica Rizzi, Kimberly Stegmaier, MD, Paolo Sportoletti, William Dalby-Brown, Giovanni Roti

Blood (2019) 134 (Supplement_1): 407.

https://doi.org/10.1182/blood-2019-125616

Published: 2019

Journal Articles

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Jode P Goodridge, PhD, Sajid Mahmood, PhD, Huang Zhu, PhD, Svetlana Gaidarova, MS, Robert Blum, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Hui-yi Chu, PhD, Greg Bonello, PhD, Tom Lee, PhD, Brian Groff, Miguel Meza, BS, Bruce Walcheck, PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Dan S Kaufman, MD PhD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 301.

https://doi.org/10.1182/blood-2019-129319

Published: 2019

Journal Articles

Risk Factors and Characteristics of CRS in CAR-T Treatment

Yan Zhiling, MD, Zhang Huanxin, MD, Ying Wang, Jiang Cao, MD, Jianlin Qiao, PhD, Deipeng Li, MD, Bin Pan, MD, Qingyun Wu, PhD, Zhenyu Li, MD, Kailin Xu, MD

Blood (2019) 134 (Supplement_1): 4462.

https://doi.org/10.1182/blood-2019-129777

Published: 2019

Journal Articles

Transcriptomic Profile of Bone Marrow-Derived Mesenchymal Stromal Cells of Pediatric Pre-B Acute Lymphoblastic Leukemia Patients and Healthy Donors after Interaction with Leukemic Cells

Tuba Özdemi̇r Sanci, MSc, Hilal Özdağ, PhD, Yasin Köksal, MSc, Seda Tasır Yılmaz, MSc, Husniye Nese Yarali, MD, Namik Yasar Özbek, MD, Habibe Meltem Özgüner, MD

Blood (2019) 134 (Supplement_1): 3957.

https://doi.org/10.1182/blood-2019-128282

Published: 2019

Journal Articles

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Marc Schwartz, MD, Lloyd E. Damon, MD, Deepa Jeyakumar, MD, Caitlin L. Costello, MD, Dimitrios Tzachanis, MD PhD, Gary J. Schiller, MD, Jesika Reiner, MPH, Matthew J. Wieduwilt, MD PhD

Blood (2019) 134 (Supplement_1): 3880.

https://doi.org/10.1182/blood-2019-131061

Published: 2019

Journal Articles

Novel Improvement of Haploidentical Hematopoietic Stem Cell Transplantation for Advanced Refractory/Relapsed Acute Leukemia

Fei Pan, Peihua Lu, Zhijie Wei, Rong Yang, Shuquan Ji, MD

Blood (2019) 134 (Supplement_1): 4593.

https://doi.org/10.1182/blood-2019-127820

Published: 2019

Journal Articles

Clinical and Cytogenomic Features of Lymphoblastic Leukemia with Intrachromosomal Amplification of Chromosome 21 (iAMP21) in the Context of Constitutional Ring Chromosome 21

Tatiana Tvrdik, PhD MSc, Kristian T. Schafernak, MD MPH, Jeffrey R Jacobsen, MD, Reha Toydemir, MD PhD, Alexandra M Walsh, MD, Bo Hong, MD

Blood (2019) 134 (Supplement_1): 5208.

https://doi.org/10.1182/blood-2019-123766

Published: 2019

Journal Articles

Clinical and Laboratory Features Associated with Flow Cytometric CD49f Expression in Pediatric B Cell Acute Lymphoblastic Leukemia

Eric McGinnis, MD BSc, David Yang, BMLSc, Nina Rolf, MD PhD, Gregor S. D. Reid, PhD, Chinten J. Lim, PhD, Suzanne M. Vercauteren, MD PhD FRCPC

Blood (2019) 134 (Supplement_1): 5209.

https://doi.org/10.1182/blood-2019-123590

Published: 2019

Journal Articles

Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia

Gregorio Campos-Cabrera, MD, Noe-Benjamin Vega-Tapia, MD, Virgina Campos-Cabrera, QFB EBC, Salvador Campos-Cabrera, MD, Jose-Luis Campos-Villagomez, MD, Esther Mendez-Garcia, MD

Blood (2019) 134 (Supplement_1): 5128.

https://doi.org/10.1182/blood-2019-127296

Published: 2019

Journal Articles

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

Shonali Midha, MD, Julio C. Chavez, MD, Hayder Saeed, MD, Celeste Bello, MD, Farhad Khimani, MD, Silvia Tse Bunting, MD MSc, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5347.

https://doi.org/10.1182/blood-2019-130721

Published: 2019

Journal Articles

Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma

Arjun Lakshman, MBBS, Cai Chen, Kayla Parr, Sarah McGregor, Sara Monaghan, MD, Steven H. Swerdlow, MD, Warren D Shlomchik, MD, Mounzer Agha, MD, Sawa Ito, MD PhD

Blood (2019) 134 (Supplement_1): 5200.

https://doi.org/10.1182/blood-2019-129257

Published: 2019

Journal Articles

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

Luke Maese, DO, Rachel E. Rau, MD, Elizabeth A. Raetz, MD, Tong Lin, Jin Zhu, Pil Kim, Reddy Chandula, Sherrie McClung, Julie Gray, Mi Rim Choi, MD, Mignon L. Loh, MD, Peter C. Adamson

Blood (2019) 134 (Supplement_1): 2586.

https://doi.org/10.1182/blood-2019-123710

Published: 2019

Journal Articles

A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling

Ashwini M Patil, MSc, Stefanie Kesper, Vishal Khairnar, PhD, Marco Luciani, Michael Möllmann, Ulrich Dührsen, Prof, MD PhD, Joachim R Göthert, PD, MD

Blood (2019) 134 (Supplement_1): 2537.

https://doi.org/10.1182/blood-2019-125331

Published: 2019

NARROW

Hyperdiploid B-lymphoblastic leukemia/lymphoma with hypereosinophilia and very few circulating lymphoblasts

Kinetics of Immune Reconstitution after CD19 CAR-T Cell Therapy in ALL Patients

MYC Oncogene Abrogates Natural Killer (NK) Cell-Mediated Immune Surveillance of B- and T- Lymphoid Malignancies By Suppressing STAT1/2-Type I IFN Signaling

Prognostic Value of Total Metabolic Tumor Volume and Total Lesion Glycolysis Measured By 18F-FDG PET-CT in Patients with T-Cell Lymphoblastic Lymphoma

Cytokine Release Syndrome Is an Independent Risk Factor Associated with Platelet Transfusion Refractoriness after CAR-T Treatment for Relapsed/Refractory Acute Lymphoblast Leukemia

CXCR4 Inhibition with BL-8040 in Combination with Nelarabine in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Coagulation FXIII-a Protein Expression Defines Three Novel Sub-Populations in Pediatric B-Cell Progenitor Acute Lymphoblastic Leukemia Characterized By Distinct Gene Expression Signatures

Targeting the Activating Mutations of NOTCH1 in T-Cell Lymphoblastic Leukemia with a New SERCA Inhibitor CAD204520

FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies

Risk Factors and Characteristics of CRS in CAR-T Treatment

Transcriptomic Profile of Bone Marrow-Derived Mesenchymal Stromal Cells of Pediatric Pre-B Acute Lymphoblastic Leukemia Patients and Healthy Donors after Interaction with Leukemic Cells

Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematologic Malignancies Consortium Study 1504

Novel Improvement of Haploidentical Hematopoietic Stem Cell Transplantation for Advanced Refractory/Relapsed Acute Leukemia

Clinical and Cytogenomic Features of Lymphoblastic Leukemia with Intrachromosomal Amplification of Chromosome 21 (iAMP21) in the Context of Constitutional Ring Chromosome 21

Clinical and Laboratory Features Associated with Flow Cytometric CD49f Expression in Pediatric B Cell Acute Lymphoblastic Leukemia

Blinatumomab and Venetoclax for Minimal Residual Disease Relapse in Acute Lymphoblastic Leukemia

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

Spontaneous Remission of Secondary Acute Lymphoblastic Leukemia Associated with Lenalidomide Therapy for Multiple Myeloma

Open-Label, Multicenter, Phase 2/3 Study of Recombinant Crisantaspase Produced in Pseudomonas Fluorescens ( RC-P) in Patients with Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL) Following Hypersensitivity to Escherichia coli -Derived Asparaginases

A CXCL10/CXCR3 Driven Thymic Epithelium-Leukemia Cell Crosstalk Augments T Cell Acute Lymphoblastic Leukemia Notch1 Signalling

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only